Position in GNLX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$1,204,000
+$599,000 QoQ
Shares Held
400,000
+60.0% QoQ
Ownership
0.884%
of shares outstanding
% of Portfolio
0.76%
of 13F equity value
Holder Rank
#6
of 72 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GNLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CM Management, LLC holds $37,311,100 across 18 Biotechnology names. GNLX ranks #10 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RIGL |
Rigel Pharmaceuticals Inc
|
250,000 | $9,780,000 | |
| 2 | RPRX |
Royalty Pharma plc
|
125,000 | $7,008,750 | |
| 3 | CHRS |
Coherus Oncology, Inc.
|
2,100,000 | $2,940,000 | |
| 4 | COYA |
Coya Therapeutics, Inc.
|
400,000 | $2,340,000 | |
| 5 | ELDN |
Eledon Pharmaceuticals, Inc.
|
575,000 | $2,265,500 | |
| 6 | LTRN |
Lantern Pharma Inc.
|
500,000 | $2,085,000 | |
| 7 | IOVA |
Iovance Biotherapeutics, Inc.
|
450,000 | $1,872,000 | |
| 8 | AVIR |
Atea Pharmaceuticals, Inc.
|
355,000 | $1,650,750 |
All Filings in GNLX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,204,000 | 400,000 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $605,000 | 250,000 | Shares | Sole | 2026-05-08 | |
| No filing history on record for this holder in this stock. | ||||||